Trial reportBlood2018
Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group.
Open access · greenAbstract readClinical TrialMulticenter Study
In one paragraph
Trial report in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 1 pooled it
13.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it, 127 citations in OpenAlex.
- A meta-analysis of diagnostic challenges in Ph-like ALL at baseline: early detection strategies for personalized therapeutic interventions.International journal of hematology · 2025Pooled it
- Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study.The Lancet. Haematology · 2021Trial
- High-risk features in adult patients with B-cell acute lymphoblastic leukemia: redefining risk in the era of targeted immunotherapy.Blood research · 2026Review
- Review
- Integrated Genomic Profiling of Pediatric Acute Lymphoblastic Leukemia: Genomic Landscape, Risk Stratification and Association of RAS Pathway Mutations with Early Treatment Response.International journal of molecular sciences · 2026Article
- From the bench of molecular understanding to the bedside of optimal therapy forEJC paediatric oncology · 2025Article
- Review
- Bridging the Gap: Cost-Effective Strategies for Detecting Ph-Like B-Lineage ALL in Resource-Limited Settings.Molecular diagnosis & therapy · 2025Review
- Review
- Diagnostic genomic analysis is prognostic in AYA patients with ALL treated on an MRD-stratified pediatric protocol.Blood neoplasia · 2025Article
- Review
- Survival prediction for Philadelphia chromosome-like acute lymphoblastic leukemia by machine learning analysis: a multicenter cohort study.Frontiers in cell and developmental biology · 2025Article
- Acute lymphoblastic leukaemia.Nature reviews. Disease primers · 2024Review
- Review
- The novel TERF2::PDGFRB fusion gene enhances tumorigenesis via PDGFRB/STAT5 signalling pathways and sensitivity to TKI in ph-like ALL.Journal of cellular and molecular medicine · 2024Article
- Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- Epidemiological and clinical characteristics of adult acute lymphoblastic leukemia patients in Chile: A single-center analysis.Leukemia research reports · 2024Article
- Comprehensive genomic characterization of hematologic malignancies at a pediatric tertiary care center.Frontiers in oncology · 2024Article
- Comprehensive detection ofFrontiers in molecular biosciences · 2024Article
- Acute lymphoblastic leukemia in young adults: which up-front treatment?.Hematology. American Society of Hematology. Education Program · 2023Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 12 institutions in 1 country.
Kathryn G RobertsDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
Shalini C ReshmiInstitute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH.
Richard C HarveyDepartment of Pathology, University of New Mexico Cancer Center, Albuquerque, NM.
I-Ming ChenDepartment of Pathology, University of New Mexico Cancer Center, Albuquerque, NM.
Kinnari PatelInstitute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH.
Eileen StonerockInstitute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH.
Heather JenkinsInstitute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH.
Yunfeng DaiDepartment of Biostatistics, University of Florida, Gainesville, FL.
Marc ValentineDepartment of Cytogenetics and.
Zhaohui GuDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
Yaqi ZhaoDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
Jinghui ZhangDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN.
Debbie Payne-TurnerDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
Meenakshi DevidasDepartment of Biostatistics, University of Florida, Gainesville, FL.
Nyla A HeeremaDepartment of Pathology, The Ohio State University, Columbus, OH.
Andrew J CarrollDepartment of Genetics, University of Alabama at Birmingham, Birmingham, AL.
Elizabeth A RaetzDepartment of Pediatrics, NYU Langone Health, New York, NY.
Michael J BorowitzDepartment of Pathology, Johns Hopkins University, Baltimore, MD.
Brent L WoodDepartment of Pathology, Seattle Children's Hospital, Seattle, WA.
Leonard A MattanoHARP Pharma Consulting, Mystic, CT.
Kelly W MaloneyDepartment of Pediatrics, University of Colorado School of Medicine and Children's Hospital, Aurora CO.
William L CarrollDepartment of Pediatrics and Perlmutter Cancer Center, NYU Langone Health, New York, NY.
Mignon L LohDepartment of Pediatrics, UCSF Benioff Children's Hospital and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA; and.
Cheryl L WillmanDepartment of Pathology, University of New Mexico Cancer Center, Albuquerque, NM.
Julie M Gastier-FosterInstitute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH.
Charles G MullighanDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
Stephen P HungerDepartment of Pediatrics, Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-5492-3957
St. Jude Children's Research Hospital · USNationwide Children's Hospital · USUniversity of New Mexico · USNYU Langone Health · USUniversity of Florida · USChildren's Hospital Colorado · USChildren's Hospital of Philadelphia · USJohns Hopkins University · USSeattle Children's Hospital · USThe Ohio State University · USUniversity of Alabama at Birmingham · USUniversity of California, San Francisco · US
Funding
NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6MViral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9MCOG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8MTranslational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3MCPML - Project 3: Genome-wide Studies of Adverse EffectsP50GM115279 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI LOH, MIGNON LEE-CHEUN, RELLING, MARY V · 2015 to 2019
$15.1MTranslating genomic discoveries to improved outcomes for high risk acute leukemiaR35CA197695 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Charles G Mullighan · 2017 to 2026
$11.4MIntegration of gene expression patterns, fusions, mutations, cytogenetics and other clinical variables for subtyping leukemias and targeting therapiesR50CA211542 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI HARVEY, RICHARD C · 2016 to 2020
$773kNCI NIH HHS P30 CA016058NCI NIH HHS P30 CA021765NCI NIH HHS R35 CA197695NCI NIH HHS R50 CA211542NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NIGMS NIH HHS P50 GM115279
Abstract
Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL;
Indexed as
Philadelphia ChromosomePrecursor B-Cell Lymphoblastic Leukemia-LymphomaAdolescentChildChild, PreschoolDisease-Free SurvivalFemaleHumansInfantMaleNational Cancer Institute (U.S.)Neoplasm ProteinsRetrospective StudiesSurvival RateUnited StatesNeoplasm Proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.